Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Up to $22.3 million BioThrax order modification from the U.S. Department of War.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Up to $22.3 million BioThrax order modification from the U.S. Department of War
- Approximately $7.4 million first delivery begins in 2026, remaining deliveries expected in 2027
- Contract supports anthrax pre-exposure prophylaxis across all U.S. military branches
- Revenue visibility for Emergent’s biodefense business, with near-term shipment activity and follow-on 2027 deliveries
Item EX-99.1 · Exhibit EX-99.1
- Up to $22.3 million BioThrax delivery-order modification from the U.S. Department of War
- Approximately $7.4 million initial delivery scheduled for 2026, with remaining deliveries expected in 2027
- Supports BioThrax supply across all U.S. military branches for anthrax pre-exposure prophylaxis
- Extends Emergent’s government anthrax franchise following approximately $24 million CYFENDUS award in August 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.